Skip to main content
Erschienen in:

27.01.2022 | Original Article

Clinicopathological characteristics and prognosis of poorly cohesive cell subtype of gastric cancer

verfasst von: Kenichi Nakamura, Kojiro Eto, Shiro Iwagami, Katsuhiro Ogawa, Hiroshi Sawayama, Takatsugu Ishimoto, Masaaki Iwatsuki, Yoshifumi Baba, Yuji Miyamoto, Naoya Yoshida, Hideo Baba

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

The new World Health Organization (WHO) classification of gastric cancer includes a histological subtype of poorly cohesive carcinoma (PCC), which includes signet-ring cell (SRC) phenotype. We aimed to examine the concordance between preoperative clinical and postoperative histological diagnoses according to the 2010 WHO histological subtypes and to compare the prognoses of these subtypes.

Methods

The study cohort comprised 665 patients who underwent gastrectomy from 2005 to 2019. Histological subtypes were classified into PCC-NOS (non-signet ring cell subtype), SRC, and non-PCC, which were defined by the predominant component in accordance with the 2010 WHO classification of gastric cancer. The concordance of clinical and pathological diagnosis was examined and clinicopathological characteristics and survival outcome of the three subtypes compared.

Results

The cancers of 443 patients (66.7%) were classified as non-PCC, of 112 patients (16.8%) as PCC-NOS, and of 110 patients (16.5%) as SRC predominant subtypes. Significant differences in sex, age, tumor location, size, macroscopic type, and pathological TNM category (all P<0.05) were found. The concordance rate of preoperative and postoperative histological subtypes was significantly lower for poorly cohesive than other subtypes (P<0.0001). Preoperative stage tended to be underestimated for PCC-NOS subtype and these patients had poorer overall survival than those with the other two subtypes (P=0.005). Multivariate logistic regression analysis of overall survival showed that WHO histological subtype (PCC-NOS vs. non-PCC/SRC, HR: 1.64, 95% CI: 1.18–2.29, P=0.0034) was a significant independent prognostic factor.

Conclusion

Our results suggest that poorly cohesive carcinoma subtypes have different biological characteristics and prognoses.
Literatur
1.
Zurück zum Zitat Lauwers GY, Carneiro F, Graham DY et al (2010) WHO classification of tumours of the digestive system, 4th edn. IARC Press, Lyon, pp 48–58 Lauwers GY, Carneiro F, Graham DY et al (2010) WHO classification of tumours of the digestive system, 4th edn. IARC Press, Lyon, pp 48–58
2.
Zurück zum Zitat Voron T, Messager M, Duhamel A et al (2016) Is signet-ring cell carcinoma a specific entity among gastric cancers? Gastric Cancer 19:1027–1040CrossRef Voron T, Messager M, Duhamel A et al (2016) Is signet-ring cell carcinoma a specific entity among gastric cancers? Gastric Cancer 19:1027–1040CrossRef
3.
Zurück zum Zitat Robb WB, Messager M, Gronnier C et al (2015) High-grade toxicity to neoadjuvant treatment for upper gastrointestinal carcinomas: what is the impact on perioperative and oncologic outcomes? Ann Surg Oncol 22:3632–9CrossRef Robb WB, Messager M, Gronnier C et al (2015) High-grade toxicity to neoadjuvant treatment for upper gastrointestinal carcinomas: what is the impact on perioperative and oncologic outcomes? Ann Surg Oncol 22:3632–9CrossRef
4.
Zurück zum Zitat Al-Batran SE, Hofheinz RD, Pauligk C et al (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 17:1697–1708CrossRef Al-Batran SE, Hofheinz RD, Pauligk C et al (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 17:1697–1708CrossRef
5.
Zurück zum Zitat Katai H, Ishikawa T, Akazawa K et al (2018) Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer 21:144–154CrossRef Katai H, Ishikawa T, Akazawa K et al (2018) Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer 21:144–154CrossRef
6.
Zurück zum Zitat Marrelli D, Pedrazzani C, Morgagni P et al (2011) Changing clinical and pathological features of gastric cancer over time. Br J Surg 98:1273–83CrossRef Marrelli D, Pedrazzani C, Morgagni P et al (2011) Changing clinical and pathological features of gastric cancer over time. Br J Surg 98:1273–83CrossRef
7.
Zurück zum Zitat Wu H, Rusiecki JA, Zhu K et al (2009) Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev 18:1945–52CrossRef Wu H, Rusiecki JA, Zhu K et al (2009) Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev 18:1945–52CrossRef
8.
Zurück zum Zitat Henson DE, Dittus C, Younes M et al (2004) Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med 128:765–70CrossRef Henson DE, Dittus C, Younes M et al (2004) Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med 128:765–70CrossRef
9.
Zurück zum Zitat Kouzu K, Tsujimoto H, Hiraki S et al (2018) Diagnostic accuracy of T stage of gastric cancer from the view point of application of laparoscopic proximal gastrectomy. Mol Clin Oncol 8:773–778PubMedPubMedCentral Kouzu K, Tsujimoto H, Hiraki S et al (2018) Diagnostic accuracy of T stage of gastric cancer from the view point of application of laparoscopic proximal gastrectomy. Mol Clin Oncol 8:773–778PubMedPubMedCentral
10.
Zurück zum Zitat Kim JH, Song KS, Youn YH et al (2007) Clinicopathologic factors influence accurate endosonographic assessment for early gastric cancer. Gastrointest Endosc 66:901–8CrossRef Kim JH, Song KS, Youn YH et al (2007) Clinicopathologic factors influence accurate endosonographic assessment for early gastric cancer. Gastrointest Endosc 66:901–8CrossRef
11.
Zurück zum Zitat Jiang CG, Wang ZN, Sun Z et al (2011) Clinicopathologic characteristics and prognosis of signet ring cell carcinoma of the stomach: results from a Chinese mono-institutional study. J Surg Oncol 103:700–3CrossRef Jiang CG, Wang ZN, Sun Z et al (2011) Clinicopathologic characteristics and prognosis of signet ring cell carcinoma of the stomach: results from a Chinese mono-institutional study. J Surg Oncol 103:700–3CrossRef
12.
Zurück zum Zitat Chon HJ, Hyung WJ, Kim C et al (2017) Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia. Ann Surg 265:946–953CrossRef Chon HJ, Hyung WJ, Kim C et al (2017) Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia. Ann Surg 265:946–953CrossRef
13.
Zurück zum Zitat Taghavi S, Jayarajan SN, Davey A et al (2012) Prognostic significance of signet ring gastric cancer. J Clin Oncol 30:3493–8CrossRef Taghavi S, Jayarajan SN, Davey A et al (2012) Prognostic significance of signet ring gastric cancer. J Clin Oncol 30:3493–8CrossRef
14.
Zurück zum Zitat Chiu CT, Kuo CJ, Yeh TS et al (2011) Early signet ring cell gastric cancer. Dig Dis Sci 56:1749–56CrossRef Chiu CT, Kuo CJ, Yeh TS et al (2011) Early signet ring cell gastric cancer. Dig Dis Sci 56:1749–56CrossRef
15.
Zurück zum Zitat Liu K, Wan J, Bei Y et al (2017) Prognostic impact of different histological types on gastric adenocarcinoma: a surveillance, epidemiology, and end results database analysis. Pathol Oncol Res 23:881–887CrossRef Liu K, Wan J, Bei Y et al (2017) Prognostic impact of different histological types on gastric adenocarcinoma: a surveillance, epidemiology, and end results database analysis. Pathol Oncol Res 23:881–887CrossRef
16.
Zurück zum Zitat Jouini R, Khanchel F, Sabbah M et al (2020) Prognostic significance of poorly cohesive gastric carcinoma in Tunisian patients. Heliyon 6:e03460. Jouini R, Khanchel F, Sabbah M et al (2020) Prognostic significance of poorly cohesive gastric carcinoma in Tunisian patients. Heliyon 6:e03460.
17.
Zurück zum Zitat Japanese Gastric Cancer A. (2020) Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. Japanese Gastric Cancer A. (2020) Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer.
18.
Zurück zum Zitat Marriette C, Carneiro F, Grabsch HI et al (2019) Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer 22:1–9CrossRef Marriette C, Carneiro F, Grabsch HI et al (2019) Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer 22:1–9CrossRef
19.
Zurück zum Zitat Kunisaki C, Akiyama H, Nomura M et al (2006) Clinicopathological properties of poorly-differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types. Anticancer Res 26:639–46PubMed Kunisaki C, Akiyama H, Nomura M et al (2006) Clinicopathological properties of poorly-differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types. Anticancer Res 26:639–46PubMed
20.
Zurück zum Zitat Fujimoto A, Ishikawa Y, Ishii T et al (2017) Differences between gastric signet-ring cell carcinoma and poorly differentiated adenocarcinoma: A comparison of histopathologic features determined by mucin core protein and trefoil factor family peptide immunohistochemistry. Pathol Int 67:398–403CrossRef Fujimoto A, Ishikawa Y, Ishii T et al (2017) Differences between gastric signet-ring cell carcinoma and poorly differentiated adenocarcinoma: A comparison of histopathologic features determined by mucin core protein and trefoil factor family peptide immunohistochemistry. Pathol Int 67:398–403CrossRef
21.
Zurück zum Zitat Terashima M, Yoshikawa T, Boku N et al (2020) Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives. Jpn J Clin Oncol 50:528–534CrossRef Terashima M, Yoshikawa T, Boku N et al (2020) Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives. Jpn J Clin Oncol 50:528–534CrossRef
22.
Zurück zum Zitat Terashima M, Iwasaki Y, Mizusawa J et al (2019) Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer 22:1044–1052CrossRef Terashima M, Iwasaki Y, Mizusawa J et al (2019) Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer 22:1044–1052CrossRef
23.
Zurück zum Zitat Zu H, Wang H, Li C et al (2014) Clinicopathologic characteristics and prognostic value of various histological types in advanced gastric cancer. Int J Clin Exp Pathol 7:5692–700PubMedPubMedCentral Zu H, Wang H, Li C et al (2014) Clinicopathologic characteristics and prognostic value of various histological types in advanced gastric cancer. Int J Clin Exp Pathol 7:5692–700PubMedPubMedCentral
24.
Zurück zum Zitat Kwon KJ, Shim KN, Song EM et al (2014) Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. Gastric Cancer 17:43–53CrossRef Kwon KJ, Shim KN, Song EM et al (2014) Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. Gastric Cancer 17:43–53CrossRef
25.
Zurück zum Zitat Kang SH, Kim JS, Moon HS et al (2017) Signet ring cell carcinoma of early gastric cancer, is endoscopic treatment really risky? Medicine (Baltimore) 96:e7532. Kang SH, Kim JS, Moon HS et al (2017) Signet ring cell carcinoma of early gastric cancer, is endoscopic treatment really risky? Medicine (Baltimore) 96:e7532.
26.
Zurück zum Zitat Kwon CH, Kim YK, Lee S et al (2018) Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognositic significance based on histopathological subtypes Kwon CH, Kim YK, Lee S et al (2018) Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognositic significance based on histopathological subtypes
Metadaten
Titel
Clinicopathological characteristics and prognosis of poorly cohesive cell subtype of gastric cancer
verfasst von
Kenichi Nakamura
Kojiro Eto
Shiro Iwagami
Katsuhiro Ogawa
Hiroshi Sawayama
Takatsugu Ishimoto
Masaaki Iwatsuki
Yoshifumi Baba
Yuji Miyamoto
Naoya Yoshida
Hideo Baba
Publikationsdatum
27.01.2022
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 3/2022
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-021-02069-6

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.